Performance of the Colorectal cancer Screening marker Sept9 is influenced by Age, Diabetes and Arthritis: a nested case-control study

Project: Research

See relations at Aarhus University


All cells in the body release circulating cell-free DNA (cfDNA) to the blood. This cfDNA can be used for both diagnosis and monitoring of disease, but also for screening purposes. Especially in cancer the methylation of cfDNA has gained much attention for early detection, as aberrant methylation of cfDNA is known to arise early in pathogenesis. The Sept9 methylation-specific blood-based marker is one of the most well-studied epigenetic screening markers of colorectal cancer, and was FDA approved in 2016.
In this study we revealed how Sept9 methylation was affected by higher age and comorbidities, which decreased the performance of the marker significantly.
Effective start/end date01/12/201501/12/2016

ID: 129050236